Ershler. W B WB; Moore. A L AL; Hacker. M P MP; Ninomiya. J J; Naylor. P P; Goldstein. A L AL
The study shows that older people make fewer antibodies after a tetanus booster, but when a thymus‑derived peptide (Thymosin Fraction 5, which includes thymosin‑α1) is added to their immune cells in the lab, it boosts antibody production, especially in the elderly. This hints that thymosin could help improve vaccine responses in older adults, though real‑world trials are still needed.
Yao. Qizhi Q; Doan. Linh X LX; Zhang. Rongxin R; Bharadwaj. Uddalak U; Li. Min M; Chen. Changyi C
The study shows that the peptide thymosin‑alpha‑1 can push blood monocytes to become more active dendritic cells, which are key players in launching immune responses. Treated cells showed higher levels of activation markers, took up less harmless antigen (meaning they’re more mature), and sparked stronger T‑cell growth and cytokine release. The effect seems to involve the p38 MAPK and NF‑κB signaling pathways.
Frasca. D D; Adorini. L L; Mancini. C C; Doria. G G
In older mice, giving the peptide thymosin‑alpha‑1 (or just its first half, called N14) boosts the activity of helper T cells, likely by raising IL‑2 production and receptor levels, while the second half (C14) does nothing. This points to a possible way to improve aging immune function, though it’s only been shown in mice so far.
In a small trial of people with chronic hepatitis B, giving the peptide thymosin‑alpha‑1 (TA‑1) for a year boosted the activity of immune cells that make important signaling proteins (cytokines) like IFN‑γ, IL‑2 and IL‑4. The boost grew over time, and a higher dose (3.2 mg) worked better than the lower dose (1.6 mg). This shows TA‑1 can ramp up both Th1 and Th2 immune pathways, especially IFN‑γ, in a disease setting.
Favalli. C C; Jezzi. T T; Mastino. A A; Rinaldi-Garaci. C C; Riccardi. C C; Garaci. E E
In mice, giving thymosin‑alpha‑1 for four days before a single dose of interferon restored natural killer (NK) cell activity that was wiped out by a chemotherapy drug, and it also sped up NK recovery after bone‑marrow transplants. This shows the two compounds work together to boost immune cells, but the work is only in animals, not people.
Older people often make fewer antibodies after a flu shot, which can leave them vulnerable. Lab tests showed that adding thymosin‑alpha‑1 to immune cells from seniors boosted the amount of flu‑specific antibodies they made. This hints that taking thymosin‑alpha‑1 at the time of vaccination might help the elderly get better protection, but real‑world trials are still needed.
Sztein. M B MB; Serrate. S A SA; Goldstein. A L AL
The study shows that thymosin‑alpha‑1, a peptide from the thymus, can boost the number of IL‑2 receptors on human immune cells in lab tests, which leads to stronger cell growth. This suggests the peptide helps the immune system work better, especially when the response is weak, like in older people or certain diseases.
This paper reviews the different thymus‑derived peptides, especially thymosin‑alpha‑1, and looks at how they affect the immune system and cancer treatment. It gathers data from lab studies and human trials, pointing out which peptides act like true hormones and summarizing their safety and effectiveness in cancer patients.
Bistoni. F F; Baccarini. M M; Puccetti. P P; Marconi. P P; Garaci. E E
In mice, giving a thymic peptide called thymostimulin (or thymosin‑alpha‑1) repeatedly for a few days makes natural killer (NK) cells more active, especially if the mice are young. The boost is strongest a couple of days after stopping the treatment. This hints the peptide could be used to ramp up immune defenses, but we don’t yet know the right dose or schedule for people.
Ishitsuka. H H; Umeda. Y Y; Nakamura. J J; Yagi. Y Y
In mice whose immune systems were weakened by a chemotherapy drug, giving thymosin‑alpha‑1 helped them survive deadly infections from fungi and bacteria. It worked at very low doses compared to older thymosin mixtures and seemed to boost the activity of immune cells like macrophages, T‑cells, and neutrophils.
Low. T L TL; Thurman. G B GB; Chincarini. C C; McClure. J E JE; Marshall. G D GD; Hu. S K SK; Goldst...
This paper shows that the thymus releases several small proteins, including thymosin‑α1, that each help different steps of T‑cell development. Thymosin‑α1 specifically boosts helper T‑cells and can turn immature immune cells into active ones. Early Phase I‑II trials suggest thymosin can aid people with weak immune systems, autoimmune issues, or cancer, hinting it could be a useful immune‑support tool, though exact dosing isn’t worked out yet.
Ohta. Y Y; Sueki. K K; Yoneyama. Y Y; Tezuka. E E; Yagi. Y Y
In mice whose immune systems were knocked down by a chemotherapy drug, a synthetic peptide called thymosin‑alpha‑1 quickly restored immune function, especially T‑cells and macrophages, at very low doses (5‑50 µg per kg). This shows the peptide can help rebuild blood‑forming cells after severe damage, but the work was done in animals, not people.
Wetzel. R R; Heyneker. H L HL; Goeddel. D V DV; Jhurani. P P; Shapiro. J J; Crea. R R; Low. T L TL;...
Scientists engineered bacteria to make thymosin‑alpha‑1, a peptide that helps the immune system. The version they produced is missing a small acetyl group at the start, but tests show it works just like the natural hormone from animal thymus.
A big review of over 11,000 people in more than 30 trials found that thymosin‑alpha‑1 is generally safe and can help the immune system in illnesses like COVID‑19, autoimmune diseases, and some cancers, challenging recent FDA limits on the peptide.
Panatto. D D; Amicizia. D D; Lai. P L PL; Camerini. R R; De Rosa. A A; Gasparini. R R
A review of studies shows that adding the peptide thymosin‑alpha‑1 (Tα1) to flu shots can boost the immune response, especially in older adults and people with weak immune systems, making the vaccine work better.
The study shows that sex hormones (like testosterone and estrogen) can directly suppress the production of thymic proteins such as thymosin‑alpha‑1 and change how thymus cells grow and mature, both through gene‑level (genomic) and quick‑acting (non‑genomic) pathways.
Zhang. Song-song SS; Li. Kun K; Wang. Yu-hui YH; Ye. Ba-ning BN; Pan. Yu Y; Shi. Xian-qing XQ
A small trial in 52 ICU patients found that giving thymosin‑alpha1 (1.6 mg subcutaneously each day for 7 days) boosted immune cell counts, delayed the onset of ventilator‑associated pneumonia and shortened both ventilator time and ICU stay, although the overall pneumonia rate was not significantly reduced.
In a study of 242 ICU patients with sepsis, adding thymosin‑alpha‑1 (1.6 mg under the skin twice a day for four days, then once daily) together with ulinastatin improved immune markers, cut the time on a ventilator, lowered the chance of organ failure, and reduced 28‑day death rates compared to standard care alone.
Zheng. Bi-xia BX; Cheng. De-yun DY; Xu. Gang G; Fan. Li-li LL; Yang. Ying Y; Yang. Wei W
In a small clinical trial, giving COPD patients 1.6 mg of thymosin‑alpha‑1 by injection ten times over a short period cut the number and length of flare‑ups and raised key immune cells (CD4 and CD4/CD8 ratio). The effect seems tied to a boost in cellular immunity, but the study was limited to sick patients and used injections, not an everyday supplement.
In mice, thymosin‑alpha‑1 (Tα1) changed the immune signaling mix, lowering several pro‑inflammatory cytokines (like IL‑1α, IL‑2, IL‑6, IL‑17) and raising the anti‑inflammatory IL‑10, especially when given together with cyclosporine A. In cell cultures, Tα1 also reduced lymphocyte growth. This points to Tα1’s ability to push the immune system toward a calmer, Th2‑type state, which could be useful for people looking to manage inflammation or support immune balance, though the study is in mice and the doses are higher than typical human use.